Answers are grounded in this paper and cite their sources.
Purpose To investigate the incidence, prevalence, associated conditions and therapeutic modalities of retinal vasculitis (RV).Methods Subjects diagnosed with RV in the TriNetX database between 2014 and 2024 were identified using the ICD-10 codes, excluding those with AIDS or HIV. The primary outcomes were the incidence and prevalence (annual and 10‑year cumulative). Demographic data, autoimmune comorbidities, immunosuppressive medication, ocular complications, and local ocular therapies at the time of or following diagnosis were collected for secondary analyses.Results From 114 907 642 subjects, 5342 cases of RV were identified. Demographic data included: 63.42% (N = 3387) women, 59.04% (N = 3154) White, 73.61% (N = 3932) Non-Hispanic or Latino and a mean age of 55 years (range 2–90). The most common autoimmune comorbidities were rheumatoid arthritis (3.88%, N = 199), sarcoidosis (3.48%, N = 179) and systemic lupus erythematosus (2.98%, N = 149). The most used systemic immunosuppressive medications were methotrexate (10.60%, N = 535), mycophenolate mofetil (9.88%, N = 502) and adalimumab (8.68%, N = 456). The most prevalent ocular complication was cystoid macular edema (21.06%, N = 956) and intravitreal injections (10.95%, N = 531) were the most frequently used procedure. Among the intravitreal agents, triamcinolone (7.07%, N = 362) was the most administered. Between 2014 and 2024, the incidence increased from 0.99 to 1.35 per 100 000 persons and the prevalence from 3.75 to 9.47 per 100 000 persons.Conclusion The rising incidence and prevalence of retinal vasculitis appear to be multifactorial, highlighting the need for interdisciplinary care, close monitoring and early intervention.
No takes yet. Share an insight, caveat, or question.
Rama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: